The phase III IMpassion131 study evaluating Tecentriq in combination with paclitaxel (chemotherapy), in comparison to placebo plus paclitaxel, did not meet statistical significance on its primary endpoint of progression-free survival for the initial (first-line) treatment of people with metastatic triple-negative breast cancer, in the PD-L1-positive population.
Over the course of his first six months as NCI director, Anthony Letai has contended with federal budget turbulence, a record-setting government shutdown, and concerns about the flow of over research dollars.
